Candel therapeutics to participate in the canaccord genuity 43rd annual growth conference

Needham, mass., aug. 02, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that paul peter tak, md, phd, fmedsci, president and chief executive officer, will participate in a fireside chat at the upcoming canaccord genuity 43rd annual growth conference, taking place august 7-10, 2023, in boston.
CADL Ratings Summary
CADL Quant Ranking